
DCPLA-ME
CAS No. 56687-67-3
DCPLA-ME( DCPLA methyl ester | Methyl 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoate | 2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester | Methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate )
Catalog No. M26146 CAS No. 56687-67-3
DCPLA-ME is the methyl ester form of DCPLA and can be used to treat neurodegenerative diseases. It is an effective PKCε activator.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 260 | In Stock |
![]() ![]() |
10MG | 410 | In Stock |
![]() ![]() |
25MG | 678 | In Stock |
![]() ![]() |
50MG | 954 | In Stock |
![]() ![]() |
100MG | 1287 | In Stock |
![]() ![]() |
500MG | 2574 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameDCPLA-ME
-
NoteResearch use only, not for human use.
-
Brief DescriptionDCPLA-ME is the methyl ester form of DCPLA and can be used to treat neurodegenerative diseases. It is an effective PKCε activator.
-
DescriptionDCPLA-ME is the methyl ester form of DCPLA and can be used to treat neurodegenerative diseases. It is an effective PKCε activator.
-
In Vitro——
-
In Vivo——
-
SynonymsDCPLA methyl ester | Methyl 8-[2-[(2-pentylcyclopropyl)methyl]cyclopropyl]octanoate | 2-[(2-Pentylcyclopropyl)methyl]cyclopropaneoctanoic acid methyl ester | Methyl 8-(2-((2-pentylcyclopropyl)methyl)cyclopropyl)octanoate
-
PathwayAngiogenesis
-
TargetPKC
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number56687-67-3
-
Formula Weight322.53
-
Molecular FormulaC21H38O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 15.62 mg/mL (48.43 mM)
-
SMILESCCCCCC1CC1CC1CC1CCCCCCCC(=O)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Solinas A, et al. Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. J Med Chem. 2012 Feb 23;55(4):1559-71.
molnova catalog



related products
-
Miltefosine
Miltefosine is used for the treatment of visceral and cutaneous leishmaniasis, and is undergoing clinical trials for this use in several other countries.
-
[Ala113]-MBP (104-11...
Synthetic peptide analog of bovine myelin basic protein (MBP). Non-competitive inhibitor of PKC (IC50 = 28 - 62 mM).
-
TPPB
TPPB is a kinase C activator of cell-permeable benzolactam-derived protein (Ki: 11.9 nM).